Therapy of angina pectoris with long-acting nitrates: Which agent and when?

Canadian Journal of Cardiology

Volumn 12, Issue SUPPL. C, 1996, Pages

  Abrams, Jonathan ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Angina pectoris; Long acting nitrates; Nitroglycerin

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; GLYCERYL TRINITRATE; NITRIC ACID DERIVATIVE;

ANGINA PECTORIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CORONARY ARTERY CONSTRICTION; CORONARY ARTERY SPASM; DRUG CHOICE; DRUG COST; DRUG TOLERANCE; HEADACHE; HEART LEFT VENTRICLE FAILURE; HUMAN; ORTHOSTATIC HYPOTENSION; SUBLINGUAL DRUG ADMINISTRATION;

ANGINA PECTORIS; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HEADACHE; HUMANS; NITROGLYCERIN; SYNCOPE; VASODILATOR AGENTS; VERTIGO;

EID: 0029895107     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol 1992;70:30B-42B.
2. Loscalzo J. Antiplatelet antithrombotic effects of organic nitrates. Am J Cardiol 1991,70:18B-22B.
3. Greenberg H, Dwyer EM, Jameson AG, et al. Effects of nitroglycerin on the major determinants of myocardial oxygen consumption. An angiographic and hemodynamic assessment. Am J Cardiol 1975;36:426-32.
4. Harrison DG, Kurz MA, Quillen JE, Mugge A. Normal and pathophysiologic considerations of endothelial regulation of vascular tone and their relevance to nitrate therapy. Circulation 1993;87:1461-7.
5. Kelly RP, Gibbs HH, Morgan JJ, et al. Nitroglycerin has more favorable effects on left ventricular afterload than apparent from measurements of pressure in peripheral artery. Eur Heart J 1990;11:138-44.
6. Haber HL, Simek CL, Bergin JD, et al. Bolus intravenous nitroglycerin predominately reduces afterload in patients with excessive arterial elastance. J Am Coll Cardiol 1993,122:251-7.
7. Mahmarian JJ, Fenimore NL, Marks GF, et al. Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201-tomography. J Am Cardiol 1994;24:25-32.
8. Fallen EL, Nahmia SC, Scheffel A, el al. Redistribution of myocardial blood flow with topical nitroglycerin in patients with coronary arterial disease. Circulation 1995;91:1381-8.
9. Fung H-L, Chung S-J, Baer JA, Chong S, Kowaluk EA. Biochemical mechanism of organic nitrate action. Am J Cardiol 1992;70:4B-10B.
10. Parker JO, Fung H-L, Ruggirello D, et al. Tolerance to isosorbide dinitrate: Rate of development and reversal. Circulation 1983;168:1074-80.
11. Parker JO, Farrell B, Lahey KA, et al. Effect of intervals between doses on the development of tolerance to isorbide dinitrate. N Engl J Med 1987;316:1440-4.
12. Silber S, Vogler AC, Krause KH, et al. Induction and circumvention of nitrate tolerance applying different dosage intervals. Am J Med 1987;83:860-70.
13. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of nitroglycerin over 24 hours. Circulation 1988;77:1376-84.
14. Elkayam U, Roth A, Mehra A, et al. Randomized study to evaluate the relationship between oral isosorbide dinitrate dosing interval and the development of early tolerance to HS effect on left ventricular pressure in patients with chronic heart failure. Circulation 1991;84 2040-8.
15. Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987;317:799-804.
16. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy in continuous twenty-four hour application of transdermal nitroglycerin. Am J Cardiol 1991;68,1263-73.
17. Mehra A, Shotan A, Ostrzega A, Vasquez-Johnson J, Elkayam U. Escalating nitrate dose overcomes early attenuation of hemodynamic effect caused by nitrate tolerance in patients with heart failure. Am Heart J 1995;1130:798-805.
18. Gogia H, Mehra A, Parikh S, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol 1996;26:1575-80.
19. Miller RR, Vismara LA, Zelis R, Amsterdam EA, Mason DT. Clinical use of sodium nitroprusside in chronic ischemic heart disease, effect on peripheral vascular resistance and venous tone on ventricular volume, pump and mechanical performance. Circulation 1975:51;328.
20. Mann T, Cohn P, Holman BL, et al. Effect of nitroprusside on regional myocardial blood flow in coronary artery disease. Results in 25 patients and comparison with nitroglycerin. Circulation 1978;57:732-8.
21. Parker JO, Amies MH, Hawkinson RW, et al. Intermittent transdermal nitroglycerin therapy in angina pectoris. Clinically effective without tolerance or rebound. Circulation 1995;91:1368-74.
22. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-93.
23. Thadani U, Maranda C, Amsterdam E, et al. Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy vath isosorbide-5-mononitrate. Ann Intern Med 1994;10:642-6.
24. Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended release isosorbide mononitrate for stable effort angina pectods. Am J Cardiol 1993;172:1249-56.
25. Parker JO, and the Isosorbide-5-Mononitrate Study Group. Eccentric dosing with isosorbide-5-mononitrate in angina pectoris. Am J Cardiol 1993;173:871-6.
26. Abrams J. Use of nitrates in ischemic heart disease. Curr Prob Cardiol 1992;17:500-6.